ArticleBMC urology2026
Efficacy of autologous adipose-derived stromal vascular fraction and platelet-rich plasma intracavernous injections in patients with erectile dysfunction: a retrospective comparative study.
Article in BMC urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVasculogenic erectile dysfunction (ED) is primarily driven by impaired penile hemodynamics, and conventional phosphodiesterase type 5 inhibitors (PDE5i) may offer limited benefit in patients with persistent endothelial dysfunction. Regenerative therapies such as platelet-rich plasma (PRP) and adipose-derived stromal vascular fraction (AD-SVF) have emerged as potential alternatives; however, comparative clinical data remain limited.
methodsThis retrospective study included 60 men with non-severe, PDE5i-refractory vasculogenic ED (International Index of Erectile Function-5 [IIEF-5] > 10) treated with either PRP (n = 30) or AD-SVF (n = 30) between April and September 2022. Changes in erectile function and penile hemodynamics were evaluated using IIEF-5 scores and peak systolic velocity (PSV) using penile Doppler ultrasonography at 3, 6, and 12 months following treatment.
resultsBoth treatment modalities were associated with significant improvements in erectile function over time. At 3 months, PRP resulted in greater short-term improvement in IIEF-5 scores compared with AD-SVF (+ 3.7 ± 2.4 vs. +1.0 ± 1.3; p < 0.001). At 6 months, AD-SVF demonstrated significantly greater improvements in IIEF-5 (+ 5.2 ± 1.7 vs. +3.7 ± 2.4; p = 0.007) and PSV (+ 3.0 ± 1.5 vs. +0.9 ± 1.1 cm/s; p < 0.001), with PRP outcomes remaining stable from 3 months onwards, indicating early functional plateau. At 12 months, AD-SVF gains were maintained (ΔIIEF-5: +5.4 ± 2.0 vs. +3.7 ± 2.4; p = 0.004; ΔPSV: +3.2 ± 1.7 vs. +1.0 ± 1.1 cm/s; p < 0.001). Subgroup analyses suggested more pronounced vascular benefits of AD-SVF in patients with hypertension and hyperlipidemia, whereas PRP showed a more uniform, moderate effect across subgroups. No serious adverse events were observed.
conclusionsIn this retrospective, real-world analysis of men with PDE5i-refractory vasculogenic ED, PRP was associated with faster short-term functional improvement, whereas AD-SVF demonstrated greater and more sustained gains from 6 months onwards. These findings should be interpreted as exploratory and hypothesis-generating, underscoring the need for prospective, controlled trials to better define the role of regenerative therapies in vasculogenic ED.
Indexed as
Identifiers
42919327What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.